Doximity Shows Rising Price Performance With Jump To 93 RS Rating

On Wednesday, Doximity (DOCS) earned an upgrade to its Relative Strength (RS) Rating, from 90 to 93.


When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. This exclusive rating from Investor’s Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price movement over the last 52 weeks stacks up against all the other stocks in our database.

Over 100 years of market history shows that the best stocks often have an RS Rating north of 80 as they begin their largest runs.

See How IBD Helps You Make More Money In Stocks

Doximity stock is now considered extended and out of buy range after clearing a 65.52 buy point in a first-stage ipo base. It has also lost much of the recent gains. It is currently trying to break through moving averages. Keep an eye for a new base to form as the overall market improves.

Top and bottom line growth moved higher in the Doximity stock’s most recent quarter. Earnings were up 700%, compared to 200% in the prior report. Revenue increased from 83% to 100%. The company is expected to report its latest numbers on or around Oct. 28.

Doximity stock earns the No. 3 rank among its peers in the Computer Software-Medical industry group. Inovalon (INOV) and Optimizerx (OPRX) are among the top 5 highly rated stocks within the group.


Join IBD Live And Learn Top Chart-Reading And Trading Techniques From The Pros
MarketSmith’s Tools Can Help The Individual Investor
Profit From Short-Term Trends With SwingTrader
Get Timely Buy & Sell Alerts With IBD Leaderboard
Find The Best Long-Term Investments With IBD Long-Term Leaders


Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button